WWW.REFERATCENTRAL.ORG.UA - Я ТУТ НАВЧАЮСЬ

... відкритий, безкоштовний архів рефератів, курсових, дипломних робіт

ГоловнаМедицина → Інфаркт міокарда (біохімічні маркери). - Курсова робота

Інфаркт міокарда (біохімічні маркери). - Курсова робота

Wienbergen L., Dawidson Е. Atypical patterns of lactate dehydrogenase isoen - zymes in acute myocardial infarction//Chn. Chem. - 1988. - Vol. 34, № 6 - P. 1096 - 1098.
23. Speich M., SalosS., Amound P N Changes in magnesium, zinc, calcium, potasium, cholesterol and creatine kinase concentrations in patients from pre - infarction syndrom to fatal myocardial infarction//Clin Chern. - 1988. - Vol. 34, № 10. - P. 2083 - 2086.
24. Zioth Т., Hukman M., Halligren R., Roxiii L. Diagnosis size estimation and prediction of acute myocardial infarction from rnyoglobin observations. A system analysis to assess the influence of various souces of variability//Scand. J. Chn. and Lab. invest. - 1980 - № 155. - P. 111 - 124. {B}
{C}M. Bertrand, M. Simoons, K. Fox,
Робоча група Європейського кардіологічного товариства
Матеріал підготував
д. м. н. О.Й. Жарінов.
Литература:
1. E. Antman, R. Handin. Low-Molecular-Weight Heparins. An Intriguing New Twist With Profound Implications. Circulation 1998; 98: 287-289.
2. J. Hirsh, S. Anand, J. Halperin, V. Fuster. Guide to Anticoagulant Therapy: Heparin. A Statement for Healthcare Professionals From the American Heart Association. Circulation 2001; 103: 2994-3018.
3. U. Cornelli, J. Fareed. Human Pharmacokinetics of Low Molecular Weight Heparins. Sem Thormb Hemost 1999; 25 (suppl. 3): 57-61.
4. ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). JACC 2000; 36: 970-1062.
5. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-1432.
6. J. Cairns, P. Theroux, H. Lewis et al. Antithrombotic Agents in Coronary Artery Disease. In: Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119 (suppl.): 228S-252S.
7. ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). JACC 1999; 33: 2092-2197.
8. ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Web Version.
9. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines). A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). JACC 2001; 37: 2239i-2239lxvi.
10. S. Levy, G. Breithardt, R. Campbell et al.on behalf of the Working Group on Arrhythmias of the European Society of Cardiology. Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J 1998; 19: 1294-1320.
11. G. Albers, J. Dalen, A. Laupacis et.al. Antithrombotic Therapy in Atrial Fibrillation. Chest 2001; 119: 194S-206S.
12. G. Frostfeldt, G. Ahlberg, G. Gustafsson et al. Low Molecular Weight Heparin (Dalteparin) as Adjuvant Treatment to Thrombolysis in Acute Myocardial Infarction - A Pilot Study: Biochemical Markers of Acute Coronary Syndromes (BIOMACS II). JACC 1999; 33: 627-633.
13. F. Kontny, J. Dale, U. Abildgaard et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. JACC 1997; 39: 962-969.
14. S. Baird, S. McBride, T. Trouton, C. Wilson. Low Molecular Weight Heparin Versus Unfractionated Heparin Following Thrombolysis in Myocardial Infarction. JACC 1998; 31 (suppl. 2A): 191A.
15. A. Glick, R. Kornowski, Y. Michowich et al. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-1148.
16. A. Ross, P. Molhoek, C. Lundergan et al. Randomized Comparison of Enoxaparin Low-Molecular-Weight Heparin With Unfractionated Hepfrin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin Second Trial of Hepfrin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648-652.
17. I. Menown, S. Baird, S. McBride et al. Evaluation of low-molecular-weight heparin in patients receiving fibrinolytic therapy for myocardial infarction. Eur Heart J 2000; 21 (abstr.suppl.): 599.
18. L. Wallentin, D. Dellborg, B. Nilsson et al. The Low-Molecular-Weight Heparin Dalteparin as Adjuvant Therapy in Acute Myocardial Infarction: the ASSENT PLUS study. Clin Cardiol 2001; 24 (suppl. I): I-12-14.
19. G. Tatu-Chitoiu, M. Oprisan, O. Cismara et al. Accelerated streptokinase (0.75 MU in 10 minutes) and enoxaparin in the prehospital management of acute myocardial infarction. Eur Heart J 1999; 20 (abstr.suppl.): 517.
20. V. Kakkar, S. Iyengar, F. De Lorenzo et al. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI). Indian Heart J 2000; 52: 533-539.
21. M. Cohen, F. Maritz, G, Gensini et al. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thronbolyzed: methods and design. J Thromb Thrombolys 2000; 10: 241-246.
22. F. Esteves, J. Braga, M. Rocha et al. Comfirmation that heparins are an alternative to promote early reperfusion - the CHEAPER study. Eur Heart J 1997; 18 (abstr.suppl.): 455.
23. F. Esteves, J. Braga, M. Rocha et al. Comfirmation that heparins are an alternative to promote early reperfusion - the CHEAPER study. Am J Cardiol 1998; 31 (suppl. C): 94C.
24. F. Kontny, J. Dale, U. Abildgaard et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. JACC 1997; 39: 962-969.
25. B. Charbonnier. Fraxiparine and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FATIV Study. Arch Mal Coeur Vaiss 1997; 90: 1215-1221.
26. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during in instability in coronary artery disease. The Lancet 1996; 347: 561-568.
27.
Loading...

 
 

Цікаве